c22c07cb-8215-47e8-9525-074fda8d7d59
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.340
- INFLAMMATORY_RESPONSE+0.310
- ALLOGRAFT_REJECTION+0.290
- TNFA_SIGNALING_VIA_NFKB+0.260
- IL6_JAK_STAT3_SIGNALING+0.250
- ANDROGEN_RESPONSE+0.230
- G2M_CHECKPOINT+0.220
- KRAS_SIGNALING_UP+0.210
- SPERMATOGENESIS+0.190
- INTERFERON_GAMMA_RESPONSE+0.180
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- MYC_TARGETS_V2-0.400
- ADIPOGENESIS-0.380
- DNA_REPAIR-0.380
- FATTY_ACID_METABOLISM-0.350
- XENOBIOTIC_METABOLISM-0.330
- ESTROGEN_RESPONSE_LATE-0.310
- CHOLESTEROL_HOMEOSTASIS-0.300
- GLYCOLYSIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b9389390-aa03-406c-957e-2bc264f9468e | — | — | 0.918 |
| 2 | TCGA-A7-A13E-01B-06R-A277-07 | — | D | 0.892 |
| 3 | AUR-AFSO-TTP1-A-8-0-R-A741-41 | — | C | 0.845 |
| 4 | AUR-AFE9-TTP1-A-1-0-R-A741-41 | — | D | 0.815 |
| 5 | 5abd486a-6aed-4dcf-a2a2-2537af6cdd9c | — | — | 0.814 |
| 6 | TCGA-CV-6939-01A-11R-1915-07 | — | — | 0.810 |
| 7 | cd10f4f7-d92b-4152-8595-332686e4605a | — | — | 0.809 |
| 8 | AUR-AER7-TTP1-A-1-0-R-A741-41 | — | D | 0.794 |
| 9 | 023160e4-1d9a-499c-9bfa-1b3aacf284f2 | — | — | 0.785 |
| 10 | TCGA-A7-A26F-01A-21R-A169-07 | — | D | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.060 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |